Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

15.19 +0.21 (+1.40%)
Official Closing Price Updated: 7:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
Via Benzinga
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
Via The Motley Fool
2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now
These two high-yield dividend stocks are attractive buys right now. 
Via The Motley Fool
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
From Takeda Pharmaceutical Company Limited
Via Business Wire
ImmunoGen Inks Pact With Takeda To Develop ELAHERE Ovarian Cancer Drug In Japan
ImmunoGen, Inc. (NASDAQ: IMGN) inked pacts with Takeda Pharmaceutical Company Limited (NYSE: TAK) to develop and  
Via Benzinga
How Is The Market Feeling About Takeda Pharmaceutical?
Via Benzinga
Why Are Poseida Therapeutics Shares Moving Higher Today?
Poseida Therapeutics Inc (NASDAQ: PSTX) shares are trading higher after the company received a $50 million strategic investment by Astellas Pharma Inc (OTC: ALMPY) (OTC: 
Via Benzinga
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
Via Benzinga
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
Via Benzinga
Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products
From Takeda Pharmaceutical Company Limited
Via Business Wire
The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
From Takeda Pharmaceutical Company Limited
Via Business Wire
Disney Considers Different Strategies For Star India, Broadcom Wins Conditional European Approval For VMware Deal, Google Deprioritizes Gen Z Chatbot App: Today's Top Stories
Wall Street Journal 
Via Benzinga
Takeda Withdraws FDA Application For Dengue Vaccine Candidate On Data Disagreement
Takeda Pharmaceutical Co Ltd (NYSE: TAK) said on Tuesday that it was voluntarily  
Via Benzinga
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic... 
Via Talk Markets
Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
ADHD Medication Shortage Worsens, Vyvanse Supply Dwindles Amid Adderall Scarcity
The supply of an alternative to Adderall, Vyvanse (lisdexamfetamine), a commonly used medication for Attention-deficit/hyperactivity disorder (ADHD), is dwindling, further limiting options for patients... 
Via Benzinga
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult... 
Via Benzinga
Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
3 AI Stocks That Could Skyrocket Your Wealth
AI is poised to greatly increase the top and bottom lines of many companies, making many AI stocks very attractive at this point. 
Via InvestorPlace
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
From HUTCHMED (China) Limited
Via GlobeNewswire
Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
From Takeda Pharmaceutical Company Limited
Via Business Wire
Seagen's Adcetris/Immunotherapy Combo Achieves 98% Overall Response Rate in Early-Stage Lymphoma Setting
Seagen Inc (NASDAQ: SGEN) announced updated efficacy and safety results from Part C of phase 2 single-arm trial of Adcetris (brentuximab vedotin) combined with nivolumab and standard chemotherapy... 
Via Benzinga
3 Stocks That Could Skyrocket by This Time Next Summer
The best stocks to skyrocket in June have all done well in 2023 and over the past year. They definitely ought to be on your watchlist. 
Via InvestorPlace
Why Shares of Innate Pharma Jumped Thursday
The company's collaboration agreement with Sanofi could soon pay off. 
Via The Motley Fool
Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
From Takeda Pharmaceutical Company Limited
Via Business Wire
FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq
The FDA approved AbbVie Inc's (NASDAQ: ABBV) Rinvoq (upadacitinib) for moderately to severely active Crohn's disease patients with inadequate response or intolerance to  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.